US2007134242A1PendingUtilityA1
Mesothelioma therapeutic agent
Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Oct 17, 2003Filed: Oct 15, 2004Published: Jun 14, 2007
Est. expiryOct 17, 2023(expired)· nominal 20-yr term from priority
A61P 35/00A61P 43/00A61K 45/06C07K 16/248C07K 2317/73C07K 2317/76C07K 2317/24C07K 16/2866A61K 39/395
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R.
Claims
exact text as granted — not AI-modified1 . A mesothelioma therapeutic agent that contains an interleukin-6 (IL-6) antagonist as its active ingredient.
2 . A mesothelioma therapeutic agent according to claim 1 wherein, the mesothelioma is pleural mesothelioma.
3 . A mesothelioma therapeutic agent according to claim 2 wherein, the pleural mesothelioma is malignant pleural mesothelioma.
4 . A mesothelioma therapeutic agent according to claim 1 wherein, the IL-6 antagonist is antibody to IL-6 receptor.
5 . A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to IL-6 receptor.
6 . A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to human IL-6 receptor.
7 . A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to mouse IL-6 receptor.
8 . A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is recombinant antibody.
9 . A mesothelioma therapeutic agent according to claim 6 wherein, the monoclonal antibody to human IL-6 receptor is PM-1 antibody.
10 . A mesothelioma therapeutic agent according to claim 7 wherein, the monoclonal antibody to mouse IL-6 receptor is MR16-1 antibody.
11 . A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is chimeric antibody, humanized antibody or human antibody.
12 . A mesothelioma therapeutic agent according to claim 11 wherein, the humanized antibody to IL-6 receptor is humanized PM-1 antibody.
13 . A growth inhibitor against mesothelioma cells that contains an interleukin-6 (IL-6) antagonist as its active ingredient.
14 . A growth inhibitor according to claim 13 wherein, the mesothelioma is pleural mesothelioma.
15 . A growth inhibitor according to claim 14 wherein, the pleural mesothelioma is malignant pleural mesothelioma.
16 . A growth inhibitor according to claim 13 wherein, the IL-6 antagonist is antibody to IL-6 receptor.
17 . A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to IL-6 receptor.
18 . A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to human IL-6 receptor.
19 . A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to mouse IL-6 receptor.
20 . A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is recombinant antibody.
21 . A growth inhibitor according to claim 18 wherein, the monoclonal antibody to human IL-6 receptor is PM-1 antibody.
22 . A growth inhibitor according to claim 19 wherein, the monoclonal antibody to mouse IL-6 receptor is MR16-1 antibody.
23 . A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is chimeric antibody, humanized antibody or human antibody.
24 . A growth inhibitor according to claim 23 wherein, the humanized antibody to IL-6 receptor is humanized PM-1 antibody.Join the waitlist — get patent alerts
Track US2007134242A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.